Skip to main content

Influenza model

Model description: influenza​

Nova’s influenza model accounts for the interplay between a viral infection and vaccination. It describes the key pathways and biomarkers influencing vaccine efficacy, including antigenic drift, strain, immunogenicity, immunosenescence, and timing of vaccination.

💊 Drugs that can be tested​

For this model, the treatments of interest are several types of vaccines, which can be administrated with different doses. The available vaccines are:

  • Split

  • Recombinant

  • mRNA

👥 Model populations of interest​

  • Adult and elderly population
  • With immunity tied to previous infections
  • vaccinated then exposed to influenza

📍Possible clinical endpoints​

  • Damage, symptoms
  • Seroprotection and seroconversion
  • At the population level, effectiveness of vaccination 

Biological submodels​

  • Vaccination
  • Virus life cycle
  • Immunization in response to vaccination or infection, and cross reactivity of different strains
  • Clinical outcomes: symptoms and damage.

Early insights to optimize your trial design: influenza model​

Vaccination​

What is the impact of the dose (Standard dose versus high dose) in split vaccines? What is the impact of vaccination timing?
What is the best vaccine type?

Patient selection​

What type of patient best benefits from vaccination ?
What is the impact of selecting older patients?
What is the impact of prior immunity?

Vaccine strain​

Given a hypothesis on the circulating strain(s), is it best to:

  1. Use a strain close to the previous seasons circulating strain?
  2. Try to anticipate the evolution of the strain?
  3. Use an antigenic-ally novel strain?